Annual EBITDA
$50.78 M
+$51.10 M+15920.56%
December 1, 2024
Summary
- As of March 10, 2025, TRDA annual EBITDA is $50.78 million, with the most recent change of +$51.10 million (+15920.56%) on December 1, 2024.
- During the last 3 years, TRDA annual EBITDA has risen by +$100.79 million (+201.55%).
- TRDA annual EBITDA is now at all-time high.
Performance
TRDA EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$4.88 M
+$15.85 M+76.47%
December 1, 2024
Summary
- As of March 10, 2025, TRDA quarterly EBITDA is -$4.88 million, with the most recent change of +$15.85 million (+76.47%) on December 1, 2024.
- Over the past year, TRDA quarterly EBITDA has stayed the same.
- TRDA quarterly EBITDA is now -108.97% below its all-time high of $54.33 million, reached on June 30, 2024.
Performance
TRDA Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
$50.78 M
-$10.52 M-17.15%
December 1, 2024
Summary
- As of March 10, 2025, TRDA TTM EBITDA is $50.78 million, with the most recent change of -$10.52 million (-17.15%) on December 1, 2024.
- Over the past year, TRDA TTM EBITDA has stayed the same.
- TRDA TTM EBITDA is now -47.57% below its all-time high of $96.87 million, reached on June 30, 2024.
Performance
TRDA TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
TRDA EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +10000.0% | 0.0% | 0.0% |
| 3 y3 years | +201.6% | +80.5% | +153.3% |
| 5 y5 years | +533.3% | +80.5% | +153.3% |
TRDA EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +153.3% | -109.0% | +80.8% | -47.6% | +153.3% |
| 5 y | 5-year | at high | +153.3% | -109.0% | +80.8% | -47.6% | +153.3% |
| alltime | all time | at high | +153.3% | -109.0% | +80.8% | -47.6% | +153.3% |
Entrada Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | $50.78 M(<-9900.0%) | -$4.88 M(-76.5%) | $50.78 M(-17.2%) |
| Sep 2024 | - | -$20.72 M(-138.1%) | $61.30 M(-36.7%) |
| Jun 2024 | - | $54.33 M(+146.4%) | $96.87 M(+259.2%) |
| Mar 2024 | - | $22.05 M(+290.8%) | $26.96 M(-8500.3%) |
| Dec 2023 | -$321.00 K(-99.7%) | $5.64 M(-62.0%) | -$321.00 K(-99.0%) |
| Sep 2023 | - | $14.85 M(-195.4%) | -$31.02 M(-56.5%) |
| Jun 2023 | - | -$15.57 M(+197.2%) | -$71.28 M(-9.6%) |
| Mar 2023 | - | -$5.24 M(-79.1%) | -$78.83 M(-17.3%) |
| Dec 2022 | -$95.35 M | -$25.05 M(-1.4%) | -$95.35 M(+7.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2022 | - | -$25.42 M(+10.0%) | -$88.40 M(+14.7%) |
| Jun 2022 | - | -$23.12 M(+6.2%) | -$77.04 M(+21.2%) |
| Mar 2022 | - | -$21.76 M(+20.3%) | -$63.58 M(+27.1%) |
| Dec 2021 | -$50.01 M(+89.9%) | -$18.10 M(+28.7%) | -$50.01 M(+23.6%) |
| Sep 2021 | - | -$14.06 M(+45.6%) | -$40.47 M(+21.6%) |
| Jun 2021 | - | -$9.66 M(+17.9%) | -$33.29 M(+40.9%) |
| Mar 2021 | - | -$8.19 M(-4.2%) | -$23.63 M(+53.1%) |
| Dec 2020 | -$26.34 M(+124.8%) | -$8.55 M(+24.3%) | -$15.44 M(+124.3%) |
| Sep 2020 | - | -$6.88 M | -$6.88 M |
| Dec 2019 | -$11.72 M | - | - |
FAQ
- What is Entrada Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Entrada Therapeutics?
- What is Entrada Therapeutics annual EBITDA year-on-year change?
- What is Entrada Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Entrada Therapeutics?
- What is Entrada Therapeutics quarterly EBITDA year-on-year change?
- What is Entrada Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Entrada Therapeutics?
- What is Entrada Therapeutics TTM EBITDA year-on-year change?
What is Entrada Therapeutics annual EBITDA?
The current annual EBITDA of TRDA is $50.78 M
What is the all time high annual EBITDA for Entrada Therapeutics?
Entrada Therapeutics all-time high annual EBITDA is $50.78 M
What is Entrada Therapeutics annual EBITDA year-on-year change?
Over the past year, TRDA annual EBITDA has changed by +$51.10 M (+15920.56%)
What is Entrada Therapeutics quarterly EBITDA?
The current quarterly EBITDA of TRDA is -$4.88 M
What is the all time high quarterly EBITDA for Entrada Therapeutics?
Entrada Therapeutics all-time high quarterly EBITDA is $54.33 M
What is Entrada Therapeutics quarterly EBITDA year-on-year change?
Over the past year, TRDA quarterly EBITDA has changed by $0.00 (0.00%)
What is Entrada Therapeutics TTM EBITDA?
The current TTM EBITDA of TRDA is $50.78 M
What is the all time high TTM EBITDA for Entrada Therapeutics?
Entrada Therapeutics all-time high TTM EBITDA is $96.87 M
What is Entrada Therapeutics TTM EBITDA year-on-year change?
Over the past year, TRDA TTM EBITDA has changed by $0.00 (0.00%)